Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Abigail B McLeodJames P SticeSuzanne E WardellHolly M AlleyChing-Yi ChangDonald P McDonnellPublished in: The Prostate (2017)
Our studies provide strong rationale for the near-term development of specific HDAC3 inhibitors for the treatment of CRPC.